CRIS Current Research Information System

GRAMENZI, ANNAGIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.205
AS - Asia 6.083
EU - Europa 4.492
AF - Africa 373
SA - Sud America 344
Continente sconosciuto - Info sul continente non disponibili 256
OC - Oceania 6
Totale 18.759
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.107
VN - Vietnam 2.140
SG - Singapore 1.486
CN - Cina 1.275
GB - Regno Unito 1.019
IT - Italia 763
SE - Svezia 635
DE - Germania 539
HK - Hong Kong 375
FR - Francia 287
IN - India 267
BR - Brasile 230
RU - Federazione Russa 217
IE - Irlanda 186
UA - Ucraina 183
NL - Olanda 155
CH - Svizzera 127
TG - Togo 114
KR - Corea 110
ZA - Sudafrica 92
JP - Giappone 84
CI - Costa d'Avorio 78
FI - Finlandia 76
EE - Estonia 75
JO - Giordania 73
BD - Bangladesh 63
BG - Bulgaria 53
CA - Canada 51
BE - Belgio 40
TH - Thailandia 37
SC - Seychelles 34
AR - Argentina 33
IR - Iran 24
EC - Ecuador 23
PH - Filippine 23
ID - Indonesia 22
GR - Grecia 21
NG - Nigeria 19
HR - Croazia 18
CL - Cile 17
ES - Italia 17
AT - Austria 16
TW - Taiwan 16
CO - Colombia 14
MX - Messico 14
PL - Polonia 14
UZ - Uzbekistan 14
PK - Pakistan 13
IQ - Iraq 12
VE - Venezuela 12
TR - Turchia 11
ET - Etiopia 10
CR - Costa Rica 9
HU - Ungheria 9
MY - Malesia 9
LB - Libano 8
CZ - Repubblica Ceca 6
EG - Egitto 6
MA - Marocco 6
PT - Portogallo 6
AE - Emirati Arabi Uniti 5
AU - Australia 5
HN - Honduras 5
LT - Lituania 5
PY - Paraguay 5
RO - Romania 5
SA - Arabia Saudita 5
DK - Danimarca 4
JM - Giamaica 4
KZ - Kazakistan 4
SV - El Salvador 4
TN - Tunisia 4
UY - Uruguay 4
MK - Macedonia 3
PE - Perù 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
BO - Bolivia 2
CG - Congo 2
DM - Dominica 2
DO - Repubblica Dominicana 2
LU - Lussemburgo 2
MU - Mauritius 2
RS - Serbia 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CV - Capo Verde 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DZ - Algeria 1
EU - Europa 1
GE - Georgia 1
GF - Guiana Francese 1
GH - Ghana 1
GL - Groenlandia 1
IS - Islanda 1
Totale 18.495
Salva come PNG Salva come JPEG
Città #
Singapore 1.021
Southend 879
Fairfield 750
Ashburn 725
Chandler 532
Ho Chi Minh City 495
Hanoi 409
San Jose 360
Hong Kong 340
Houston 334
Woodbridge 334
Dong Ket 326
Seattle 284
Wilmington 267
Santa Clara 253
Cambridge 242
Ann Arbor 229
Princeton 213
Bologna 199
Dublin 185
Hefei 182
Beijing 166
Boardman 161
Council Bluffs 153
Bern 116
Lomé 114
Jacksonville 110
Lauterbourg 106
Los Angeles 95
Dallas 91
Seoul 88
Westminster 88
New York 86
Da Nang 85
Abidjan 78
Milan 77
Padova 77
Nanjing 75
Amman 72
Tokyo 69
Haiphong 62
Berlin 60
Redmond 57
Helsinki 56
Shenyang 52
Jinan 50
Sofia 50
Buffalo 48
Munich 46
Saint Petersburg 45
San Diego 43
Florence 42
São Paulo 42
Turin 40
Brussels 39
Changsha 39
Frankfurt am Main 34
Hải Dương 33
Guangzhou 30
Redondo Beach 29
Bremen 27
Phoenix 27
Tianjin 27
Medford 26
Nanchang 24
Shanghai 24
Dearborn 23
Des Moines 23
Biên Hòa 22
Can Tho 22
Falkenstein 22
Hebei 22
Rome 22
London 20
Paris 20
Thái Nguyên 20
Zhengzhou 20
Chicago 19
Hangzhou 19
Jiaxing 19
Mülheim 19
Wuhan 19
Abeokuta 18
Amsterdam 18
Bengaluru 18
Norwalk 18
Orem 18
Vũng Tàu 18
Bến Tre 17
Ha Long 17
Falls Church 16
Mahé 16
Turku 16
The Dalles 15
Bangkok 14
Bắc Ninh 14
Montreal 14
San Francisco 14
Nha Trang 13
Nuremberg 13
Totale 12.136
Salva come PNG Salva come JPEG
Nome #
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 521
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 333
Monofocal hepatocellular carcinoma: How much does size matter? 301
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 294
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 271
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 246
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 246
Pattern of macrovascular invasion in hepatocellular carcinoma 246
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 244
Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation 244
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study 241
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 240
Computed Tomography-Colonography With Intravenous Contrast Medium and Urographic Phase for the Evaluation of Pelvic Deep Infiltrating Endometriosis of Intestinal and Urinary Tract 238
Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. 237
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation. 230
A new prognostic model to predict drop-out from the waiting list in cirrhotic candidates for liver transplantation wirh MELD score <18. 230
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 226
BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. 225
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 219
Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma 219
The changing scenario of hepatocellular carcinoma in Italy: an update 217
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 213
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib 211
Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20 year multicentre experience. 209
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 209
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 209
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 209
Hepatitis C Virus-related chronic liver disease in elderly patients: an Italian cross-sectional study. 207
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 207
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 207
Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial 205
Vitamins in the treatment of chronic viral hepatitis. 203
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients 202
Metabolic disorders across hepatocellular carcinoma in Italy 201
Serum hepatitis B surface antigen monitoring in long-term Lamivudine-treated hepatitis B virus patients 200
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 199
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. 196
Alcoholic liver disease: pathophisiological aspects and risk factors. A review. 194
Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis. Effects on cancer staging and patients survival. 192
Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis 191
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. 189
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 188
Stem cell mobilization and collection in patients with liver cirrhosis. 186
Liver transplantation for patients with alcoholic liver disease: an open question 185
In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B. 181
Development and validation of a scoring system that includes corrected QT interval for risk analysis of patients with cirrhosis and gastrointestinal bleeding 181
High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alfa-2b and Ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? 179
Hepatitis B virus and immune response. 175
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin 172
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 172
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing Lamivudine resistance. 171
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study. 168
Two years Mycophenolate Mofetil plus low dose calcineurin inhibitor for renal dysfunction after liver transplantation. 168
In vitro effect of indomethacin and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C 168
Immunological modifications during treatment with thymosin alpha 1 plus antiviral therapy in chronic hepatitis C. 167
Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis 167
Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. 167
Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. 165
null 164
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 157
Reply to “Re: Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma—A Propensity Analysis” 157
Years of life that could be saved from prevention of hepatocellular carcinoma. 156
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 156
Probiotics History. 156
Authors’ reply: Comment to “Liver transplantation for patients with alcoholic liver disease: An open question” 154
Hepatitis C virus (HCV) infection in elderly patients: A multicenter Italian cross-sectional study 153
Redefinition of diagnostic role of inferior vena cava ultrasonography in the identification of acute heart failure. 153
Ketoprofen, peginterferon-alpha2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. 153
Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. 152
Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: which is the winner? 150
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C. 149
The evolutionary scenario of hepatocellular carcinoma in Italy: an update. 149
Reply to: "Sorafenib or (90) Y loaded resin microsphere radioembolization for locally-advanced hepatocellular carcinoma, what should we trust?" 145
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case controlled study 143
Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? 140
Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study 139
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis 138
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS). 135
TRANS-ARTERIAL RADIOEMBOLIZATION FOR INTERMEDIATE-ADVANCED HEPATOCELLULAR CARCINOMA: A BUDGET IMPACT ANALYSIS 135
Vitamin E as treatment for chronic viral hepatitis: is it time to perform large clinical trials? 133
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 133
La radioembolizzazione nel trattamento del colangiocarcinoma intraepatico inoperabile: efficacia, sopravvivenza e sicurezza 129
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE. 124
Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival 123
PEGYLATED INTERFERON PLUS RIBAVIRIN FOR THE TREATMENT OF RECURRENT HCV INFECTION AFTER LIVER TRANSPLANTATION 122
Hepatic artery stenosis in liver transplanted patients treated with pegylated Interferon alpha-2b and Ribavirin 120
null 117
Capitolo 14 "Epatiti Virali Croniche", Volume IX "Malattie del Fegato, delle Vie Biliari e del Pancreas", Trattato di Medicina Interna, fondato da Paolo Larizza 114
Hepatitis C in the elderly: a multicenter cross-sectional study by the Italian Association for the Study of the Liver. 113
Senility 111
Radioembolizzazione con 90Y versus sorafenib nei pazienti cirrotici con carcinoma epatocellulare (HCC): studio monocentrico con analisi di propensity 109
Post-transplantation lymphoproliferative disorders in liver transplanted patients: a report of four cases 107
SPONTANEOUS MOBILIZATIONOF BONE MARROW-DERIVED HEMATOPOIETIC AND ENDOTHELAIL PROGENITOR CELLS AFTER ORTHOTOPIC LIVER TRANSPALNTATION (OLT). 106
Fegato e infezioni sistemiche. 104
Role of CT colonography (CTC) in a regional colorectal cancer (CRC) screening programme: preliminary results. 103
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE 101
Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? 97
Yttrium90 radioembolization versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis 90
Sorafenib versus Y90 radioembolization in cirrhotic patients with hepatocellular carcinoma (HCC): cohort and nested control-case study with propensity analysis 90
Prognosis of untreated hepatocellular carcinoma. 85
Totale 17.946
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.541
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.541
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.990 0 86 121 202 170 121 56 134 63 166 550 321
2022/20232.379 231 364 112 314 120 189 87 119 398 80 189 176
2023/2024628 51 95 40 56 59 150 17 45 29 31 23 32
2024/20252.330 89 362 193 189 350 142 178 59 16 167 127 458
2025/20266.065 709 431 504 336 550 337 965 219 1.163 469 186 196
2026/2027236 130 106 0 0 0 0 0 0 0 0 0 0
Totale 18.759